Saltar al contenido
Merck
Todas las fotos(1)

Documentos

SAB4300137

Sigma-Aldrich

Anti-phospho-PRKDC (pThr2609) antibody produced in rabbit

affinity isolated antibody

Sinónimos:

Anti-DNA-PKcs antibody produced in rabbit, Anti-DNAPK antibody produced in rabbit, Anti-DNPK1 antibody produced in rabbit, Anti-HYRC antibody produced in rabbit, Anti-protein kinase, DNA-activated, catalytic polypeptide antibody produced in rabbit

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Número MDL:
MFCD01321942
Código UNSPSC:
12352203
NACRES:
NA.41

origen biológico

rabbit

conjugado

unconjugated

forma del anticuerpo

affinity isolated antibody

tipo de anticuerpo

primary antibodies

clon

polyclonal

formulario

buffered aqueous solution

mol peso

~450 kDa

reactividad de especies

human

concentración

1 mg/mL

técnicas

western blot: 1:500-1:1000

isotipo

IgG

secuencia del inmunógeno

(V-E-TP-Q-A)

Nº de acceso NCBI

NP_001075109.1

Nº de acceso UniProt

P78527

Condiciones de envío

wet ice

temp. de almacenamiento

−20°C

modificación del objetivo postraduccional

phosphorylation (pThr2609)

Información sobre el gen

human ... PRKDC(5591)

Inmunógeno

Peptide sequence around phosphorylation site of threonine 2609 (V-E-T(p)-Q-A), according to the protein PRKDC.

Características y beneficios

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Descripción de destino

The PRKDC gene encodes the catalytic subunit of a nuclear DNA-dependent serine/threonine protein kinase (DNA-PK). The second component is the autoimmune antigen Ku (MIM 152690), which is encoded by the G22P1 gene on chromosome 22q. On its own, the catalytic subunit of DNA-PK is inactive and relies on the G22P1 component to direct it to the DNA and trigger its kinase activity; PRKDC must be bound to DNA to express its catalytic properties.

Forma física

Solution in phosphate-buffered saline containing 0.02% sodium azide and 50% glycerol

Cláusula de descargo de responsabilidad

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Herramienta de selección de productos.

Código de clase de almacenamiento

10 - Combustible liquids

Clase de riesgo para el agua (WGK)

WGK 1

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Jessica A Neal et al.
DNA repair, 73, 7-16 (2018-11-10)
DNA-PKcs deficiency has been studied in numerous animal models and cell culture systems. In previous studies of kinase inactivating mutations in cell culture systems, ablation of DNA-PK's catalytic activity results in a cell phenotype that is virtually indistinguishable from that
Huanrong Ma et al.
International journal of cancer, 142(12), 2578-2588 (2018-01-25)
Cetuximab resistance is a key barrier in treating metastatic colorectal cancer (mCRC). Targeting of metabolic resources import could resensitize drug-resistant cancer cells to anticancer treatments. Here we showed that the expression of the glutamine transporter solute carrier 1 family member
Changhoon Choi et al.
PloS one, 14(6), e0218049-e0218049 (2019-06-14)
Recent studies have highlighted the implications of genetic variations in the relative biological effectiveness (RBE) of proton beam irradiation over conventional X-ray irradiation. Proton beam radiotherapy is a reasonable radiotherapy option for hepatocellular carcinoma (HCC), but the impact of genetic
Sissel Hauge et al.
Cell cycle (Georgetown, Tex.), 18(8), 834-847 (2019-04-05)
The Wee1 inhibitor MK1775 (AZD1775) is currently being tested in clinical trials for cancer treatment. Here, we show that the p53 target and CDK inhibitor p21 protects against MK1775-induced DNA damage during S-phase. Cancer and normal cells deficient for p21

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico